Fecal Microbiota Transplant (FMT) is gaining traction as a potentially effect treatment of the increasing number of diseases that have been linked to microbiome dysbiosis.
To look for associations between the gut microbiome composition and development of Type 2 Diabetes, CMIT collaborated with researchers at institutes and hospitals within Mexico to study a cohort that had not been been diagnosed with, or treated for T2D, avoiding the potential influences of medication and lifestyle changes on gut microbes.
CMIT is collaborating with Dr. Patricia Pringle and Dr. Raymond Chung from Massachusetts General Hospital (MGH) on a new study that is investigating the potential role of fecal microbiota transplantation (FMT) as a treatment for hepatic encephalopathy.